Immune cell tweak aims to tame type 1 diabetes in tiny trial
NCT ID NCT07395050
First seen Feb 17, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This early-stage study tests whether specially engineered immune cells (CD6-CAR Tregs) are safe and feasible for 6 adults with stage 3 type 1 diabetes. The cells are designed to calm the immune attack on insulin-producing cells, but the goal is disease control, not a cure. Participants will be monitored for side effects and changes in insulin needs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 3 TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.